Chantal Fournier-Wirth

Dr. Chantal Fournier-Wirth

Pathogenesis and Control of Chronic and Emerging Infections- French Blood Establishment
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DBDaisy Bougard
Daisy Bougard
JBJean-Philippe Brandel
Jean-Philippe Brandel
MBMaxime Bélondrade
Maxime Bélondrade
VBVincent Béringue
Vincent Béringue
CSChristiane Segarra
Christiane Segarra
JCJoliette Coste
Joliette Coste
A sensitive blood diagnostic assay can identify patients with variant Creutzfeldt-Jakob disease before symptoms appear and during the clinical phase.

1 April 2014 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
SISarra El Ichi
Sarra El Ichi
FLFanny Leon
Fanny Leon
LVLudivine Vossier
Ludivine Vossier
HMHelene Marchandin
Helene Marchandin
AEAbdelhamid Errachid
Abdelhamid Errachid
CFChantal Fournier-Wirth
Chantal Fournier-Wirth

26 February 2020 in mSphere
Verified
Journal Article
Open access
PDF file
MBMaxime Bélondrade
Maxime Bélondrade
CJChristelle Jas-Duval
Christelle Jas-Duval
SNSimon Nicot
Simon Nicot
LBLilian Bruyère-Ostells
Lilian Bruyère-Ostells
CMCharly Mayran
Charly Mayran
DBDaisy Bougard
Daisy Bougard
Creutzfeldt-Jakob diseases are neurodegenerative disorders for which transmission linked to medical procedures have been reported in hundreds of patients. As prion diseases, they are characterized by an unusual resistance to conventional decontamination processes. Moreover, their large tissue distribution and the ability of prions to attach to many surfaces raised the risk of transmission in health care facilities. It is therefore of major importance that decontamination procedures applied to medical devices before their reprocessing are thoroughly validated for prion inactivation. We previously described an in vitro assay, which allowed us to classify accurately prion decontamination treatments according to their efficacy on variant Creutzfeldt-Jakob disease. The significance of this study is in demonstrating the concordance between previous in vitro results and infectivity studies in transgenic mice. Furthermore, commercial reagents currently used in hospitals were tested by both protocols, and we observed that most of them were ineffective on human prions.

1 July 2018 in Emerging Infectious Diseases
Verified
Journal Article
Open access
DBDaisy Bougard
Daisy Bougard
MBMaxime Bélondrade
Maxime Bélondrade
CMCharly Mayran
Charly Mayran
LBLilian Bruyère-Ostells
Lilian Bruyère-Ostells
SLSylvain Lehmann
Sylvain Lehmann
AGAlison J.E. Green
Alison J.E. Green
A patient with a heterozygous variant of Creutzfeldt-Jakob disease (CJD) with a methionine/valine genotype at codon 129 of the prion protein gene was recently reported. Using an ultrasensitive and specific protein misfolding cyclic amplification-based assay for detecting variant CJD prions in cerebrospinal fluid, we discriminated this heterozygous case of variant CJD from cases of sporadic CJD.

29 May 2018 in Analytical Chemistry
Verified
Journal Article
Closed access
JGJulien Gomez-Martinez
Julien Gomez-Martinez
MSMonique Silvy
Monique Silvy
JCJacques Chiaroni
Jacques Chiaroni
CFChantal Fournier-Wirth
Chantal Fournier-Wirth
FRFrancis Roubinet
Francis Roubinet
JBJean-Charles Henri Brès
Jean-Charles Henri Brès

1 January 2010 in Biologicals
Verified
Journal Article
Closed access
CFChantal Fournier-Wirth
Chantal Fournier-Wirth
JCJoliette Coste
Joliette Coste